Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 22 of 23
Jan 16, 2026In a move to streamline operations and concentrate resources, Vedanta Biosciences, a Cambridge-based biotech company, recently laid off half of its workforce and furloughed many others. This restructuring aims to prioritize the upcoming Phase III study of its lead candidate targeting C. difficile infections.
TCB Team
Jan 16, 2026Market rumors suggest that Sanofi may be looking to acquire Ocular Therapeutix, whose lead drug candidate, Axpaxli, targets wet age-related macular degeneration. The ongoing Phase III trial results expected this quarter could be pivotal for the company’s future and the takeover possibilities.
TCB Team
Jan 16, 2026Bispecific antibodies, which simultaneously target two different antigens, are capturing significant interest within cancer research and pharmaceutical dealmaking. Takeda’s strategic deal reflects both the promising clinical potential and the commercial value attributed to this innovative class of therapeutics.
TCB Team
Jan 15, 2026Day 4 of the J.P. Morgan Healthcare Conference featured in-depth discussions with Regeneron’s chief scientist George Yancopoulos, market forecasts for biotech IPOs, and close attention on Johnson & Johnson’s strategic moves.
TCB Team
Jan 15, 2026On the third day of the J.P. Morgan Healthcare Conference, rare diseases took center stage as industry experts and drugmakers outlined critical developments slated for 2026. This year promises to be transformative with a pipeline rich in potential approvals and strategic filings that could redefine treatment landscapes for rare conditions.
TCB Team
Jan 14, 2026AstraZeneca is positioning itself for substantial growth over the next decade. Key to its plan are advanced therapeutic modalities including antibody-drug conjugates (ADCs) and cell therapies, alongside a robust pipeline of products under FDA review targeting significant medical needs.
TCB Team
Jan 14, 2026At the 2026 J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal revealed why the pharmaceutical giant is choosing to focus its resources away from GLP-1 agonists. This post explores the rationale behind Novartis’ approach and discusses the broader implications for the industry as GLP-1 drugs continue to proliferate.
TCB Team
Jan 13, 2026Sarepta's 2026 pipeline includes advanced siRNA therapies for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1, aiming at a forecasted $1 billion market opportunity per program. Despite recent hurdles, the company targets a year full of development catalysts and growth potential.
TCB Team
Jan 13, 2026Pfizer’s strategic move to fast-track its obesity treatment follows critical patent cliffs on key products. The accelerated development timeline reflects the company’s proactive efforts to sustain its market presence and address a growing public health concern.
TCB Team
Jan 13, 2026AbbVie's significant investment signals a strategic effort to strengthen its oncology pipeline through a novel bispecific antibody developed in China. Targeting PD-1 and VEGF, the modality is at the forefront of emerging cancer therapies vying for market dominance.
TCB Team
Jan 13, 2026While many large biopharma companies prioritize late-stage asset acquisitions, Bristol Myers Squibb is the notable exception actively securing partnerships with early-stage biotech innovators. Its collaborations with companies like insitro and Orbital Technologies illustrate a forward-looking approach aiming to shape the future of biopharmaceutical innovation.
TCB Team
Jan 12, 2026Facing challenges with the commercial performance of its flagship product, Alnylam is charting a course for growth and resilience. This plan reflects a commitment to advancing gene-silencing technology and expanding their pipeline to meet unmet medical needs.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.